CTI BIOPHARMA CORP (CTIC)       5.615  +0.11 (+1.91%)

5.615  +0.11 (+1.91%)

US12648L6011 - Common Stock

CTI BIOPHARMA CORP5.615

NASDAQ:CTIC (12/7/2022, 2:11:02 PM)+0.11 (+1.91%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-07 2022-11-07/amc Earnings (Next) 03-29 2023-03-29
Ins Owners 0.63% Inst Owners 77.21%
Market Cap 712.51M Shares 126.89M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 03-21 1997-03-21

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CTIC Daily chart

Company Profile

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 121 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Company Info

CTI BIOPHARMA CORP

3101 Western Ave Ste 800

Seattle WASHINGTON 98121

P: 12062827100.0

CEO: Adam R. Craig

Employees: 121

Website: https://www.ctibiopharma.com/

CTIC News

News Image6 days ago - FinancialNewsMedia.comResearch and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

/PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells or...

News Image6 days ago - FinancialNewsMediaResearch and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

News Image7 days ago - CTI BioPharma Corp.CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and...

News Image16 days ago - Market News VideoInteresting CTIC Put And Call Options For January 2023News Imagea month ago - CTI BioPharma Corp.CTI BioPharma to Present at Upcoming November Conferences

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in...

News Imagea month ago - CTI BioPharma Corp.CTI BioPharma Reports Third Quarter 2022 Financial Results

/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022....

CTIC Twits

Here you can normally see the latest stock twits on CTIC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example